retatrutide clinical trial results 2024 2025 press release Phase 3: 60% Achieved Surgical-Level Weight Loss Retatrutide 2026: 28.3% Weight Loss

Plan the exit before you plan the start

334-OR: Pemvidutide (ALT-801), a Balanced (1:1) GLP-1/Glucagon dual receptor agonist, induces rapid and marked weight loss without the need for dose titration in people with overweight/obesity

doi: 10.2337/diacare.28.5.1083 27 SniderKEBeckerSBoyajianLShyngS-LMacMullenCHughesNet al

Journal of Clinical Medicine, 14 (3), 812

Retatrutide restores metabolic flexibility more effectively than tirzepatide, due to: Glucagon-induced lipolysis and fat oxidation Enhanced mitochondrial function Thermogenesis via uncoupling proteins (e.g., UCP-1) in brown fat This promotes not only weight loss but a true reversal of metabolic disease , supporting long-term maintenance and vitality

Staying hydrated and eating protein-rich foods during week one supports tolerance and stabilizes blood sugar